Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase 1b Study of Ibrutinib Combined With R-DHAP or R-DHAOx in Patients With B-cell Lymphomas

Trial Profile

A Phase 1b Study of Ibrutinib Combined With R-DHAP or R-DHAOx in Patients With B-cell Lymphomas

Status: Discontinued
Phase of Trial: Phase I

Latest Information Update: 18 Oct 2018

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Ibrutinib (Primary) ; Cisplatin; Cytarabine; Dexamethasone; Oxaliplatin; Rituximab
  • Indications B-cell lymphoma; Mantle-cell lymphoma
  • Focus Adverse reactions
  • Acronyms BIBLOS
  • Most Recent Events

    • 09 Oct 2018 Status changed from recruiting to discontinued.
    • 05 Jun 2018 Results (n=12) presented at the 54th Annual Meeting of the American Society of Clinical Oncology.
    • 18 Apr 2018 Results of Population pharmacokinetic modeling of ibrutinib presented at the 109th Annual Meeting of the American Association for Cancer Research
Restricted Access

If your organization has a subscription then there are several options available to help you access AdisInsight while working remotely. Contact us at AsktheExpert.AdisInsight@springer.com to find out more.
Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top